The rebranding of Ranbaxy drugs sold in the United States is part of an overall strategy to turn around the company that has been hit hard with quality and GMP-related issues. The Ranbaxy brand name is likely to continue to be present in markets outside of the U.S., Reuters sources said.

Sun's Ranbaxy revival plan also includes making Ranbaxy's India plants FDA quality-compliant, lobbying the U.S. FDA to lift bans on imports from Ranbaxy's plants and management restructuring to boost oversight of Indian plants.

Bayer has exercised its option, under a change-in-control clause in the collaboration agreement with Loxo Oncology, to obtain the exclusive licensing rights for the global development and commercialization of two cancer drugs.

A mix of feature articles and current new stories that are critical to staying up-to-date on the industry, delivered to your inbox. Choose from an assortment of different topics and frequencies. Subscribe Today.